Federal contract award

75A50122C00070

THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEVELOP AND COMMERCIALIZE A RAPID PHENOTYPIC ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) SYSTEM THAT WILL DELIVER RESULTS FOR DEFINITIVE THERAPEUTIC DECISIONS WITHIN 4 TO 6 HOURS FROM COLONIES ON A CULTURE

Research the contractorView USAspending sourceSave to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

FieldReported value
AgencyDepartment of Health and Human Services
OfficeBARDA - ASPR / DAAPPO / BARDA DCMA
NAICS541714 — Research and Development in Biotechnology (except Nanobiotechnology)
PSCAN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
Parent award / vehicleNot reported
Set-asideNO SET ASIDE USED.
Pricing typeCOST SHARING
Obligations$36.7M
Current contract value$36.7M
Potential contract value / ceiling$65.2M
Start dateSep 30, 2022
Current end dateSep 29, 2026
Potential end dateMay 20, 2028
Latest award activityMar 27, 2026
Source loadedSep 26, 2026

Funding and modification history

Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.

DateModificationObligation changeDescription
Mar 27, 2026P00005$0THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEVELOP AND COMMERCIALIZE A RAPID PHENOTYPIC ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) SYSTEM THAT WILL DELIVER RESULTS FOR DEFINITIVE THERAPEUTIC DECISIONS WITHIN 4 TO 6 HOURS FROM COLONIES ON A CULTURE
Oct 25, 2024P00004$0THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEVELOP AND COMMERCIALIZE A RAPID PHENOTYPIC ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) SYSTEM THAT WILL DELIVER RESULTS FOR DEFINITIVE THERAPEUTIC DECISIONS WITHIN 4 TO 6 HOURS FROM COLONIES ON A CULTURE
Feb 29, 2024P00003$0THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEVELOP AND COMMERCIALIZE A RAPID PHENOTYPIC ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) SYSTEM THAT WILL DELIVER RESULTS FOR DEFINITIVE THERAPEUTIC DECISIONS WITHIN 4 TO 6 HOURS FROM COLONIES ON A CULTURE
Dec 20, 2023P00002$0THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEVELOP AND COMMERCIALIZE A RAPID PHENOTYPIC ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) SYSTEM THAT WILL DELIVER RESULTS FOR DEFINITIVE THERAPEUTIC DECISIONS WITHIN 4 TO 6 HOURS FROM COLONIES ON A CULTURE
Sep 22, 2023P00001$21.7MTHE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEVELOP AND COMMERCIALIZE A RAPID PHENOTYPIC ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) SYSTEM THAT WILL DELIVER RESULTS FOR DEFINITIVE THERAPEUTIC DECISIONS WITHIN 4 TO 6 HOURS FROM COLONIES ON A CULTURE
Sep 29, 20220$15.0MTHE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEVELOP AND COMMERCIALIZE A RAPID PHENOTYPIC ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) SYSTEM THAT WILL DELIVER RESULTS FOR DEFINITIVE THERAPEUTIC DECISIONS WITHIN 4 TO 6 HOURS FROM COLONIES ON A CULTURE

Estimated positioning window

May 20, 2027 – Nov 20, 2027

Recompete signal:
70/100

Why this recompete signal

Contract timing and recorded acquisition signals at the time of calculation.

Stored score: 70/100. Available recorded signals: 65 points.

Contract end 2028-05-20 (566 days from calculation)
+25 points
121 historical awards in this buyer and category group
+15 points
6 recorded award transactions
+10 points
Latest award action: 2026-03-27
+5 points
Parent award identifier recorded
+0 points
Solicitation identifier recorded
+10 points
Linked official forecast
+0 points
Calculated on
2026-11-01 10:17:53.997580+00:00

The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.

Rule-based research score; it does not measure your chance of winning.

This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.

USAspending award record

. Rule-based research score; positioning dates are estimates.

Recompete score calculated Nov 1, 2026.

Research next steps

  1. Check the linked forecast or SAM for a confirmed solicitation and current timing.
  2. Verify whether remaining options may extend performance beyond the current end date.
  3. Check the stated set-aside against the solicitation and current certifications.
  4. Review the award scope and buyer evidence before making a bid/no-bid decision.